{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:02:33Z","timestamp":1789448553700,"version":"build-2803163510"},"reference-count":184,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007458","name":"Qatar Foundation","doi-asserted-by":"crossref","award":["59700.1.1390031"],"award-info":[{"award-number":["59700.1.1390031"]}],"id":[{"id":"10.13039\/100007458","id-type":"DOI","asserted-by":"crossref"}]},{"award":["59700.1.1390031"],"award-info":[{"award-number":["59700.1.1390031"]}],"id":[{"id":"https:\/\/ror.org\/01cawbq05","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Poly(ADP-ribose) polymerase inhibitors (PARPis) have transformed the treatment landscape of homologous recombination-deficient malignancies, particularly BRCA1\/2-mutant breast, ovarian, pancreatic, and prostate cancers. In contrast, clinical studies evaluating PARPis in broadly selected colorectal cancer (CRC) patients have yielded disappointing outcomes despite evidence that a subset of CRCs harbor DNA damage response (DDR) defects and homologous recombination deficiency (HRD)-associated mutational signatures. These observations highlight the need for improved patient stratification and the development of strategies to enhance PARPi sensitivity in CRC. In this review, we integrate CRC-specific evidence with mechanistic and preclinical findings from other malignancies and discuss candidate biomarkers associated with PARPi responsiveness, including TP53, RAD51, and MRE11, and examine their potential utility in identifying CRC patient populations most likely to benefit from PARP inhibition. We further summarize therapeutic approaches aimed at inducing \u201cBRCAness\u201d and sensitizing CRC cells to PARPis through epigenetic modulation, targeting cell-cycle checkpoint regulators, inhibiting growth factor signaling pathways, and exploiting metabolic vulnerabilities. Emerging strategies involving polyamine inhibition and modulation of NAD+ metabolism have been specifically highlighted for their potential role in therapeutic response. Collectively, these approaches provide a framework for investigating mechanistically compelling opportunities to overcome intrinsic and acquired resistance to PARPis and expand the clinical utility of DDR-targeted therapies in CRC. A deeper mechanistic understanding of PARPi response and resistance, in addition to extensive investigations in CRC-specific models and molecularly selected clinical cohorts, will facilitate the development of biomarker-driven combination therapies and improve outcomes for patients with CRC.<\/jats:p>","DOI":"10.3390\/ijms27188127","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:09:51Z","timestamp":1789387791000},"page":"8127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies"],"prefix":"10.3390","volume":"27","author":[{"given":"Mariam","family":"Elesnawy","sequence":"first","affiliation":[{"name":"Biological Sciences, Carnegie Mellon University Qatar, Doha 24866, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5878-5218","authenticated-orcid":false,"given":"Eman","family":"Masood","sequence":"additional","affiliation":[{"name":"Biological Sciences, Carnegie Mellon University Qatar, Doha 24866, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-3869","authenticated-orcid":false,"given":"Adviti","family":"Naik","sequence":"additional","affiliation":[{"name":"Biological Sciences, Carnegie Mellon University Qatar, Doha 24866, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dem\u00e9ny, M.A., and Vir\u00e1g, L. (2021). The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks. Cancers, 13.","DOI":"10.3390\/cancers13092042"},{"key":"ref_2","first-page":"328","article-title":"PARP-1 and PARP-2: New players in tumour development","volume":"1","author":"Yelamos","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11250","DOI":"10.1093\/nar\/gkz820","article-title":"Poly(ADP-ribose)-dependent chromatin unfolding facilitates the association of DNA-binding proteins with DNA at sites of damage","volume":"47","author":"Smith","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1126\/science.1177321","article-title":"Poly(ADP-ribose)\u2013Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1","volume":"325","author":"Ahel","year":"2009","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1093\/nar\/gky334","article-title":"CHD3 and CHD4 recruitment and chromatin remodeling activity at DNA breaks is promoted by early poly(ADP-ribose)-dependent chromatin relaxation","volume":"46","author":"Smith","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103873","DOI":"10.1016\/j.dnarep.2025.103873","article-title":"Multiple functions of PARP1 in the repair of DNA double strand breaks","volume":"152","author":"Ortega","year":"2025","journal-title":"DNA Repair"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1101\/gad.226357.113","article-title":"The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response","volume":"27","author":"Li","year":"2013","journal-title":"Genes Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1074\/jbc.M706734200","article-title":"PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites","volume":"283","author":"Haince","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tang, J., Curull, V., Wang, X., Ampurdan\u00e9s, C., Duran, X., Pijuan, L., Rodr\u00edguez-Fuster, A., Aguil\u00f3, R., Y\u00e9lamos, J., and Barreiro, E. (2020). Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD. Cancers, 12.","DOI":"10.3390\/cancers12113333"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15541","DOI":"10.1021\/acs.jmedchem.0c01346","article-title":"Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bochum, S., Berger, S., and Martens, U. (2018). Olaparib. Small Molecules in Oncology. Recent Results in Cancer Research, Springer. Cancer Treat. Res.","DOI":"10.1007\/978-3-319-91442-8_15"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/cas.15477","article-title":"Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes","volume":"113","author":"Onji","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_16","unstructured":"U.S. Food and Drug Administration (2025). LYNPARZA (Olaparib) Tablets, for Oral Use: Prescribing Information."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gou, R., Horikawa, N., and Kosaka, K. (2022). Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer. BMJ Case Rep., 15.","DOI":"10.1136\/bcr-2022-249177"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1758835920921980","DOI":"10.1177\/1758835920921980","article-title":"Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting","volume":"12","author":"Tookman","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","article-title":"Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination","volume":"58","author":"Jones","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_21","unstructured":"U.S. Food and Drug Administration (2025). ZEJULA (Niraparib) Tablets, for Oral Use: Prescribing Information."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s11523-021-00841-2","article-title":"Niraparib: A review in first-line maintenance therapy in advanced ovarian cancer","volume":"16","author":"Lee","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1158\/1078-0432.CCR-25-0883","article-title":"FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer","volume":"31","author":"Maguire","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40487-021-00167-z","article-title":"An in-depth review of niraparib in ovarian cancer: Mechanism of action, clinical efficacy and future directions","volume":"9","author":"Akay","year":"2021","journal-title":"Oncol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, J., Xiao, D., Liu, L., Xie, F., Li, W., Sun, W., and Zhou, X. (2020). Design, synthesis, and in vitro evaluation of the photoactivatable prodrug of the PARP inhibitor talazoparib. Molecules, 25.","DOI":"10.3390\/molecules25020407"},{"key":"ref_26","unstructured":"U.S. Food and Drug Administration (2025). TALZENNA (Talazoparib) Capsules, for Oral Use: Prescribing Information."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.23.02182","article-title":"US Food and Drug Administration approval summary: Talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Heiss","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: First approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, N., Liu, Q., Tian, Y., and Wu, L. (2022). Overview of fuzuloparib in the treatment of ovarian cancer: Background and future perspective. J. Gynecol. Oncol., 33.","DOI":"10.3802\/jgo.2022.33.e86"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","article-title":"Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor","volume":"22","author":"Xiong","year":"2020","journal-title":"Neoplasia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_34","first-page":"1479","article-title":"Phase 1A\/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours","volume":"125","author":"Lickliter","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41698-024-00672-0","article-title":"The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors","volume":"8","author":"Incorvaia","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41580-020-00297-8","article-title":"The molecular basis and disease relevance of non-homologous DNA end joining","volume":"21","author":"Zhao","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Munj, S.A., Taz, T.A., Arslanturk, S., and Heath, E.I. (2022). Biomarker-driven drug repurposing on biologically similar cancers with DNA-repair deficiencies. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.1015531"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wang, S.S.Y., Jie, Y.E., Cheng, S.W., Ling, G.L., and Ming, H.V.Y. (2023). PARP Inhibitors in Breast and Ovarian Cancer. Cancers, 15.","DOI":"10.3390\/cancers15082357"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41573-025-01273-7","article-title":"Synthetic lethality in cancer drug discovery: Challenges and opportunities","volume":"25","author":"Ryan","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","volume":"81","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Guo, M., and Wang, S.M. (2022). The BRCAness Landscape of Cancer. Cells, 11.","DOI":"10.3390\/cells11233877"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res."},{"key":"ref_46","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"SOLO2\/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Ledermann","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib Versus Nonplatinum Chemotherapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1\/2 Mutation (SOLO3): A Randomized Phase III Trial","volume":"38","author":"Penson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","volume":"1","author":"Abida","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Valsecchi, A.A., Dionisio, R., Panepinto, O., Paparo, J., Palicelli, A., Vignani, F., and Di Maio, M. (2023). Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15092435"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline Mutations in ATM and BRCA1\/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2019.37.15_suppl.5005","article-title":"TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations","volume":"37","author":"Mateo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis from the phase 2 TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): An open-label, phase 2 trial","volume":"22","author":"Mehra","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17588359231221337","DOI":"10.1177\/17588359231221337","article-title":"Development of PARP inhibitors in advanced prostate cancer","volume":"16","author":"Bourlon","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"104430","DOI":"10.18632\/oncotarget.22303","article-title":"High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy","volume":"8","author":"Roda","year":"2017","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review)","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2010.12.002","article-title":"PARP Inhibitor Treatment in Ovarian and Breast Cancer","volume":"35","author":"Weil","year":"2011","journal-title":"Curr. Probl. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrm3719","article-title":"Double-strand break repair: 53BP1 comes into focus","volume":"15","author":"Panier","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2019.01.015","article-title":"53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer","volume":"153","author":"Hurley","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: The underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Sasaki, Y., Inouchi, T., Nakatsuka, R., Inoue, A., Masutani, M., and Nozaki, T. (2024). Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0302130"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2018.10.045","article-title":"USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors","volume":"72","author":"Lim","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13578-023-01117-0","article-title":"MRE11:P.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC","volume":"13","author":"Zhuang","year":"2023","journal-title":"Cell Biosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Hossain, M.S., Karuniawati, H., Jairoun, A.A., Urbi, Z., Ooi, D.J., John, A., Lim, Y.C., Kibria, K.M.K., Mohiuddin, A.K.M., and Ming, L.C. (2022). Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers, 14.","DOI":"10.3390\/cancers14071732"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rawla, P., Barsouk, A., Hadjinicolaou, A.V., and Barsouk, A. (2019). Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. Med. Sci., 7.","DOI":"10.3390\/medsci7080083"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_81","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17588359211072703","DOI":"10.1177\/17588359211072703","article-title":"Precision medicine for metastatic colorectal cancer in clinical practice","volume":"14","author":"Riedesser","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Gilson, A., Tan, V., Koessler, T., Meyer, J., Meurette, G., Liot, \u00c9., Ris, F., and Delaune, V. (2025). Immune Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review. Cancers, 17.","DOI":"10.3390\/cancers17132125"},{"key":"ref_84","first-page":"337","article-title":"An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer","volume":"23","author":"Mo","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/1878-0261.12467","article-title":"Exploiting DNA repair defects in colorectal cancer","volume":"13","author":"Reilly","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"102923","DOI":"10.1016\/j.ebiom.2020.102923","article-title":"Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity","volume":"59","author":"Smeby","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"114036","DOI":"10.1016\/j.ejca.2024.114036","article-title":"Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study","volume":"205","author":"Takashima","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41416-018-0343-z","article-title":"A phase 2 randomised study of veliparib plus FOLFIRI\u00b1bevacizumab versus placebo plus FOLFIRI\u00b1bevacizumab in metastatic colorectal cancer","volume":"120","author":"Gorbunova","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10637-016-0351-x","article-title":"A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187","volume":"34","author":"Chen","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1634\/theoncologist.2015-0319","article-title":"Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer","volume":"21","author":"Leichman","year":"2016","journal-title":"Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/cncr.31309","article-title":"A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer","volume":"124","author":"Pishvaian","year":"2018","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2468-1253(17)30012-2","article-title":"Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: A phase 1b study","volume":"2","author":"Czito","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2023.41.4_suppl.7","article-title":"Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)","volume":"41","author":"George","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_94","first-page":"272","article-title":"A Phase II, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair-Proficient Colorectal or Pancreatic Cancer","volume":"23","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1200\/JCO.2023.41.16_suppl.3579","article-title":"Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer","volume":"41","author":"Alese","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/2767-9764.CRC-23-0045","article-title":"Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer","volume":"3","author":"Cecchini","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_97","unstructured":"(2020). Trifluridine\/Tipiracil and Talazoparib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer, ClinicalTrials.gov. NCT04511039."},{"key":"ref_98","unstructured":"(2021). A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers, ClinicalTrials.gov. NCT04926324."},{"key":"ref_99","unstructured":"(2022). Pembrolizumab and Olaparib in Homologous Recombination Deficient (HRD) Advanced Colorectal Cancer, ClinicalTrials.gov. NCT05201612."},{"key":"ref_100","unstructured":"(2023). The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-Line Treatment in Patients with Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer, ClinicalTrials.gov. NCT05732129."},{"key":"ref_101","unstructured":"(2024). Niraparib and Dostarlimab for Patients with MMR-D\/MSI-H Colorectal Cancers, ClinicalTrials.gov. NCT06365970."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","article-title":"Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: A phase I study","volume":"30","author":"Samol","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2011). Integrated Genomic Analyses of Ovarian Carcinoma. Nature, 474, 609\u2013615. Correction in Nature\u00a02012, 490, 292. https:\/\/doi.org\/10.1038\/nature11453.","DOI":"10.1038\/nature10166"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Puentes-Pardo, J.D., Moreno-SanJuan, S., Casado, J., Escudero-Feliu, J., L\u00f3pez-P\u00e9rez, D., S\u00e1nchez-Uceta, P., Gonz\u00e1lez-Novoa, P., G\u00e1lvez, J., Carazo, \u00c1., and Le\u00f3n, J. (2023). PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054787"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.embor.7400587","article-title":"P53 modulates homologous recombination by transcriptional regulation of the RAD51 gene","volume":"7","author":"Kerr","year":"2006","journal-title":"EMBO Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-19-2409","article-title":"A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin","volume":"26","author":"Arena","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-10-1120","article-title":"MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite instable colorectal cancers","volume":"71","author":"Vilar","year":"2011","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Takamatsu, S., Brown, J.B., Yamaguchi, K., Hamanishi, J., Yamanoi, K., Takaya, H., Kaneyasu, T., Mori, S., Mandai, M., and Matsumura, N. (2022). Utility of homologous recombination deficiency biomarkers across cancer types. JCO Precis. Oncol., 6.","DOI":"10.1200\/PO.22.00085"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102728","DOI":"10.1016\/j.xcrm.2026.102728","article-title":"Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives","volume":"7","author":"Fei","year":"2026","journal-title":"Cell Rep. Med."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Storandt, M.H., and Sinicrope, F.A. (2026). Deficient mismatch repair\/microsatellite instability-high colorectal cancer: Current treatment paradigms, limitations and future perspectives. BMJ Oncol., 5.","DOI":"10.1136\/bmjonc-2025-000980"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Alfahed, A. (2025). PARP Inhibition in Colorectal Cancer\u2014A Comparison of Potential Predictive Biomarkers for Therapy. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060905"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12935-015-0162-8","article-title":"Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI\/MSS status","volume":"15","author":"Kuznicki","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"22609","DOI":"10.1073\/pnas.1903765116","article-title":"DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation","volume":"116","author":"Abbotts","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"17785","DOI":"10.1073\/pnas.2003499117","article-title":"Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency","volume":"117","author":"McLaughlin","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2016.03.007","article-title":"Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin","volume":"45","author":"Robert","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.18632\/oncotarget.23386","article-title":"Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells","volume":"9","author":"Valdez","year":"2017","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Zhang, J., Yang, C., Wu, C., Cui, W., and Wang, L. (2020). DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy. Cancers, 12.","DOI":"10.3390\/cancers12082123"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00384-009-0664-8","article-title":"Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer","volume":"24","author":"Zhang","year":"2009","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/febs.15730","article-title":"Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer","volume":"288","author":"Chen","year":"2021","journal-title":"FEBS J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.18632\/oncotarget.24291","article-title":"Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage","volume":"9","author":"Caruso","year":"2018","journal-title":"Oncotarget"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","article-title":"EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition","volume":"37","author":"Karakashev","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.20517\/cdr.2022.73","article-title":"New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers","volume":"6","author":"Bayley","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"key":"ref_128","first-page":"1140","article-title":"CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer","volume":"10","author":"Li","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Abbotts, R., Dellomo, A.J., and Rassool, F.V. (2022). Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use. Cancers, 14.","DOI":"10.3390\/cancers14112640"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","article-title":"Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition","volume":"71","author":"Haynes","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"111026","DOI":"10.18632\/oncotarget.22195","article-title":"Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer","volume":"8","author":"Brill","year":"2017","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"Hirai","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., and Oka, S. (2024). WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. Cancers, 16.","DOI":"10.3390\/cancers16183136"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41389-018-0116-9","article-title":"Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1","volume":"8","author":"Chakraborty","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4032","article-title":"Blocking c-Met\u2013mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat. Med."},{"key":"ref_140","first-page":"608","article-title":"Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells","volume":"9","author":"Han","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_141","first-page":"648","article-title":"Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer","volume":"10","author":"Chu","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.18632\/oncotarget.24294","article-title":"MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models","volume":"9","author":"Vena","year":"2018","journal-title":"Oncotarget"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K Inhibition Impairs BRCA1\/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","article-title":"mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer","volume":"22","author":"Mo","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1593\/neo.131694","article-title":"Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness","volume":"16","author":"De","year":"2014","journal-title":"Neoplasia"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: A dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10549-025-07747-x","article-title":"Phase I\/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1\/2 positive, HER2 negative breast cancers","volume":"212","author":"Phadke","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Alblihy, A., Ali, R., Algethami, M., Ritchie, A.A., Shoqafi, A., Alqahtani, S., Mesquita, K.A., Toss, M.S., Ord\u00f3\u00f1ez-Mor\u00e1n, P., and Jeyapalan, J.N. (2023). Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310966"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"117226","DOI":"10.1016\/j.ejmech.2024.117226","article-title":"Discovery of new inhibitors of nuclease MRE11","volume":"285","author":"Nikulenkov","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2147\/OTT.S322297","article-title":"Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead","volume":"15","author":"Tsang","year":"2022","journal-title":"OncoTargets Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"699","DOI":"10.18632\/oncotarget.28651","article-title":"Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition","volume":"15","author":"Rackear","year":"2024","journal-title":"Oncotarget"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"11227","DOI":"10.1038\/s41598-019-47600-y","article-title":"A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51","volume":"9","author":"Pastushok","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2021.39.15_suppl.3006","article-title":"First-in-human phase I\/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers","volume":"39","author":"Lynch","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/acs.jmedchem.5c02624","article-title":"Development of Novel PROTAC RAD51 Degraders as Enhancers of DNA Damage Response for Hepatocellular Carcinoma Treatment","volume":"69","author":"Huang","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","article-title":"Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1","volume":"72","author":"Ying","year":"2012","journal-title":"Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Koppensteiner, R., Samartzis, E.P., Noske, A., von Teichman, A., Dedes, I., Gwerder, M., Imesch, P., Ikenberg, K., Moch, H., and Fink, D. (2014). Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100041"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.freeradbiomed.2017.09.008","article-title":"Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis","volume":"113","author":"Ma","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_159","first-page":"2629","article-title":"Pharmacological ascorbate induces \u201cBRCAness\u201d and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1\/2 wild-type ovarian cancer","volume":"19","author":"Ma","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Wang, F., He, M.-M., Wang, Z.-X., Li, S., Jin, Y., Ren, C., Shi, S.-M., Bi, B.-T., Chen, S.-Z., and Lv, Z.-D. (2019). Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5696-z"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biocel.2009.07.009","article-title":"Modulation of cellular function by polyamines","volume":"42","author":"Igarashi","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"C164","DOI":"10.1152\/ajpcell.00512.2009","article-title":"The role of spermidine\/spermine N1-acetyltransferase in endotoxin-induced acute kidney injury","volume":"299","author":"Zahedi","year":"2010","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41467-018-08011-1","article-title":"Promotion of homology-directed DNA repair by polyamines","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"14269","DOI":"10.1038\/s41598-019-50543-z","article-title":"Polyamine supplementation reduces DNA damage in adipose stem cells cultured in 3-D","volume":"9","author":"Minguzzi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1074\/jbc.RA119.012376","article-title":"Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy","volume":"295","author":"Geck","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Massaro, C., Thomas, J., and Phanstiel Iv, O. (2017). Investigation of Polyamine Metabolism and Homeostasis in Pancreatic Cancers. Med. Sci., 5.","DOI":"10.3390\/medsci5040032"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41467-021-20896-z","article-title":"Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/1878-0261.13789","article-title":"The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma","volume":"19","author":"Azfar","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"904","DOI":"10.7150\/ijms.93903","article-title":"Natural Product Quercetin-3-methyl ether Promotes Colorectal Cancer Cell Apoptosis by Downregulating Intracellular Polyamine Signaling","volume":"21","author":"Zeng","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Xiang, B., Geng, R., Ji, X., Wang, D., Yin, Z., Chen, L., and Liu, J. (2026). Targeting Polyamine Metabolism in Colorectal Cancer: Apigenin Dismantles the HIF-1\u03b1\/SMOX Positive Feedback Loop to Suppress Tumor Progression. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27073261"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s42255-020-0253-2","article-title":"Polyamine pathway activity promotes cysteine essentiality in cancer cells","volume":"2","author":"Zhang","year":"2020","journal-title":"Nat. Metab."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-cancerbio-030518-055905","article-title":"NAD+ Metabolism in Aging and Cancer","volume":"3","author":"Demarest","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1091\/mbc.E18-10-0650","article-title":"NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival","volume":"30","author":"Murata","year":"2019","journal-title":"Mol. Biol. Cell"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1101\/gad.335109.119","article-title":"Interplay between compartmentalized NAD+ synthesis and consumption: A focus on the PARP family","volume":"34","author":"Cohen","year":"2020","journal-title":"Genes Dev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","article-title":"NAD+ metabolism: Pathophysiologic mechanisms and therapeutic potential","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Yaku, K., Okabe, K., Hikosaka, K., and Nakagawa, T. (2018). NAD Metabolism in Cancer Therapeutics. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00622"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1158\/1078-0432.CCR-17-1121","article-title":"Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma","volume":"23","author":"Heske","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/ars.2018.7722","article-title":"Cellular Compartmentation and the Redox\/Nonredox Functions of NAD+","volume":"31","author":"Kulkarni","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Navas, L.E., and Carnero, A. (2022). Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer. Cells, 11.","DOI":"10.3390\/cells11172627"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cmet.2011.03.004","article-title":"PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation","volume":"13","author":"Bai","year":"2011","journal-title":"Cell Metab."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Ji, L.L., and Yeo, D. (2022). Maintenance of NAD+ Homeostasis in Skeletal Muscle during Aging and Exercise. Cells, 11.","DOI":"10.3390\/cells11040710"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Kang, B.E., Choi, J.-Y., Stein, S., and Ryu, D. (2020). Implications of NAD+ boosters in translational medicine. Eur. J. Clin. Investig., 50.","DOI":"10.1111\/eci.13334"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"8819627","DOI":"10.1155\/2020\/8819627","article-title":"Healthy Lifestyle Recommendations: Do the Beneficial Effects Originate from NAD+ Amount at the Cellular Level?","volume":"2020","author":"Poljsak","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Alese, O.B., Wu, C., Chapin, W.J., Ulanja, M.B., Zheng-Lin, B., Amankwah, M., and Eads, J. (2023). Update on Emerging Therapies for Advanced Colorectal Cancer. Am. Soc. Clin. Oncol. Educ. Book, 43.","DOI":"10.1200\/EDBK_389574"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:16:48Z","timestamp":1789445808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":184,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188127"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188127","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]}}}